Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study.
作者信息
Masi Paul, Hékimian Guillaume, Lejeune Manon, Chommeloux Juliette, Desnos Cyrielle, Pineton De Chambrun Marc, Martin-Toutain Isabelle, Nieszkowska Ania, Lebreton Guillaume, Bréchot Nicolas, Schmidt Matthieu, Edouard Luyt Charles, Combes Alain, Frere Corinne
机构信息
Medical Intensive Care Unit (P.M., G.H., J.C., C.D., M.P.D.C., A.N., N.B., M.S., C.E.L., A.C.), Department of Hematology (M.L., I.M.-T., C.F.), and Cardiothoracic Surgery Department (G.L.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, France. Sorbonne Université, INSERM UMRS_1166, Institute of Cardiometabolism and Nutrition, Paris, France (G.H., G.L., M.S., C.E.L., A.C., C.F.).
出版信息
Circulation. 2020 Aug 11;142(6):611-614. doi: 10.1161/CIRCULATIONAHA.120.048925. Epub 2020 Jun 17.
Abstract
摘要
相似文献
1
Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study.
Circulation. 2020 Aug 11;142(6):611-614. doi: 10.1161/CIRCULATIONAHA.120.048925. Epub 2020 Jun 17.
2
Insights into pediatric multi-system inflammatory syndrome and COVID-19.
Clin Chim Acta. 2020 Nov;510:121-122. doi: 10.1016/j.cca.2020.07.025. Epub 2020 Jul 14.
3
The unique characteristics of COVID-19 coagulopathy.
Crit Care. 2020 Jun 18;24(1):360. doi: 10.1186/s13054-020-03077-0.
4
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
5
Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC).
Elife. 2020 Aug 17;9:e59209. doi: 10.7554/eLife.59209.
6
[Coagulopathy and COVID-19. Recommendations for a changing reality].
Medicina (B Aires). 2020;80(5):505-511.
7
[Dealing with COVID-19-associated coagulopathy].
Ned Tijdschr Geneeskd. 2020 Apr 15;164:D5031.
8
COVID-19 and coagulative axis: review of emerging aspects in a novel disease.
Monaldi Arch Chest Dis. 2020 May 19;90(2). doi: 10.4081/monaldi.2020.1300.
9
Characteristics of Pediatric Inflammatory Multisystem Syndrome Associated with COVID-19.
Am J Nurs. 2020 Nov;120(11):1. doi: 10.1097/01.NAJ.0000721968.57773.b2.
10
A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic.
Thromb Res. 2020 Aug;192:73-74. doi: 10.1016/j.thromres.2020.05.024. Epub 2020 May 16.
引用本文的文献
1
Coagulation and inflammatory markers independently predict in-hospital mortality in aspiration pneumonia patients undergoing bronchoalveolar lavage.
Am J Transl Res. 2025 Jun 15;17(6):4601-4611. doi: 10.62347/BAQD6951. eCollection 2025.
2
Heterogeneity of the Immunological and Pathogenic Profiles in Patients Hospitalize Early Versus Late During an Acute Vital Illness as Shown in Native SARS-CoV-2 Infection.
Int J Mol Sci. 2025 Mar 6;26(5):2349. doi: 10.3390/ijms26052349.
3
Viscoelastic Study of Hemostasis Disorders Associated with Envenoming in North Benin Using a Quantra Analyzer.
Toxins (Basel). 2024 Dec 24;17(1):3. doi: 10.3390/toxins17010003.
4
COVID-19 in the Initiation and Progression of Atherosclerosis: Pathophysiology During and Beyond the Acute Phase.
JACC Adv. 2024 Jul 17;3(8):101107. doi: 10.1016/j.jacadv.2024.101107. eCollection 2024 Aug.
5
Immediate Clinical Complications Occurring During Membrane Change in Patients on Veno-Venous Extracorporeal Membrane Oxygenation.
ASAIO J. 2025 Feb 1;71(2):120-127. doi: 10.1097/MAT.0000000000002270. Epub 2024 Jul 25.
6
COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?
Int J Mol Sci. 2024 Feb 12;25(4):2212. doi: 10.3390/ijms25042212.
7
Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus.
Cardiovasc Diabetol. 2024 Feb 20;23(1):75. doi: 10.1186/s12933-023-02097-8.
8
Proinflammatory cytokines driving cardiotoxicity in COVID-19.
Cardiovasc Res. 2024 Mar 13;120(2):174-187. doi: 10.1093/cvr/cvad174.
9
Non-bacterial thrombotic endocarditis in a patient with COVID.
BMJ Case Rep. 2023 Oct 21;16(10):e256264. doi: 10.1136/bcr-2023-256264.
10
Comparison of the Efficacy and Safety Profiles of Different P2Y12 Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction in the COVID-19 Era.
Cureus. 2023 Aug 20;15(8):e43829. doi: 10.7759/cureus.43829. eCollection 2023 Aug.
本文引用的文献
1
Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.
Intensive Care Med. 2020 Aug;46(8):1603-1606. doi: 10.1007/s00134-020-06088-1. Epub 2020 May 15.
2
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.
3
COVID-19 and its implications for thrombosis and anticoagulation.
Blood. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020006000.
4
Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence.
Circulation. 2020 Jul 14;142(2):184-186. doi: 10.1161/CIRCULATIONAHA.120.047430. Epub 2020 Apr 24.
5
Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms.
Blood. 2019 Feb 28;133(9):906-918. doi: 10.1182/blood-2018-11-882993. Epub 2019 Jan 14.
Zotero 插件